Related Experiment Videos

Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with

R Kaufmann1, U Junker, M Schilli-Westermann

  • 1Research Laboratory, Department of General and Visceral Surgery, Institute of Immunology, Medical Faculty at the Friedrich Schiller University Jena, Research Center Lobeda, Germany. roland.kaufmann@med.uni-jena.de

Oncology Reports
|February 13, 2003
PubMed

Insights

Meizothrombin (MT) activates renal cell carcinoma (RCC) cells, similar to thrombin, by engaging PAR-1 and PAR-3 receptors. This suggests MT, a thrombin precursor, plays a role in RCC progression.

Area of Science:

  • Biochemistry
  • Oncology
  • Cell Biology

Background:

  • Meizothrombin (MT), a prothrombin intermediate, activates brain tumor cells via PAR-1 receptors.
  • Its role in renal cell carcinoma (RCC) is not well understood.

Purpose of the Study:

  • To investigate the effect of recombinant human MT (rMT) on calcium mobilization in primary human RCC cultures.
  • To determine the specific thrombin receptors involved in rMT-mediated RCC cell activation.

Main Methods:

  • Primary human RCC cell cultures were established.
  • Calcium mobilization was measured in response to rMT and thrombin stimulation.
  • PAR-type specific antibodies were used to identify involved receptors.

Main Results:

  • rMT rapidly induced transient calcium mobilization in RCC cells, similar to thrombin.
  • Stimulation with thrombin after rMT (and vice versa) did not elicit a new calcium response, indicating shared pathways.
  • PAR-1 and PAR-3 receptors were implicated in rMT-induced calcium signaling.

Conclusions:

  • rMT is a potent activator of human RCC cells.
  • Both thrombin and MT may play significant roles in human renal cell carcinoma.
  • rMT's activation mechanism in RCC involves PAR-1 and PAR-3 receptors.

Related Concept Videos